This news is a significant negative catalyst for REGENXBIO, as a clinical hold on a key drug candidate for Hunter Syndrome, coupled with the decision not to resubmit the BLA in the near term, signals a major setback. This will likely lead to a substantial decline in the company's stock price and raise questions about its pipeline and future revenue prospects.
The FDA's clinical hold on RGX-121, a crucial gene therapy for Hunter Syndrome, is a severe blow to REGENXBIO. The 'asymptomatic spine MRI findings' raise safety concerns, and the company's decision not to resubmit the BLA in the near term indicates a significant delay, potentially requiring further studies or modifications. This directly impacts RGNX's valuation, as RGX-121 was a key pipeline asset. Investors will likely re-evaluate the company's risk profile and future growth trajectory, leading to a sharp sell-off. This event also casts a shadow on the broader gene therapy sector, particularly for companies with similar delivery mechanisms or targeting rare diseases, as regulatory scrutiny might increase.